Green Sands Equity

Paradromics, Inc. is focused on developing brain-machine interfaces that facilitate data transmission between the brain and machines, primarily targeting the treatment of neurodegenerative diseases. The company creates implantable systems capable of decoding complex neural recordings into data streams, which can be utilized by various neural prostheses. Its technology emphasizes high-volume, bidirectional data streaming, allowing patients with neurological disorders to reconnect with their environment and compensate for lost biological connectivity. Founded in 2015 and headquartered in Austin, Texas, Paradromics also offers applications to support its product suite, aiming to enhance the quality of life for individuals with disabilities.

ArsenalBio is a programmable cell therapy company focused on creating effective and accessible immune cell therapies, particularly for cancer patients. Established in 2019, the company integrates advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to revolutionize the discovery and development of immune cell therapies. ArsenalBio employs a comprehensive research and development approach to produce multifunctional T-cell therapies, utilizing the precise insertion of large synthetic DNA sequences. The company's mission is to enhance the efficacy and safety of immune cell therapies while reducing costs for providers and expanding access for patients. Through its innovative framework, ArsenalBio aims to significantly improve treatment outcomes for a broader patient population.

Colossal Biosciences is an innovative firm in the field of bioscience and genetic engineering, focused on advancing genomics technology. The company is dedicated to developing transformative solutions for the restoration of extinct species, protection of critically endangered species, and the repopulation of essential ecosystems. Utilizing CRISPR technology, Colossal aims to facilitate species de-extinction, starting with the woolly mammoth, thereby enabling environmental organizations to rehabilitate ecosystems and promote biodiversity. Through its efforts, Colossal seeks to address ecological challenges while also considering the economic and biological needs of humanity.

USA Rare Earth LLC, founded in 2019 and based in New York, focuses on the exploration and processing of critical minerals, including rare earth elements, lithium, uranium, and beryllium. The company's primary project, located in Hudspeth County, Texas, is the Round Top Deposit, which is noted for its extensive range of heavy rare earth elements and other high-value tech minerals. Round Top is recognized as one of the lowest-cost rare earth projects globally and hosts 13 of the 35 minerals classified as "critical" by the Department of the Interior, essential for national defense and industrial applications. USA Rare Earth aims to establish itself as a key supplier of heavy rare earth materials for the U.S. Department of Defense, addressing the country’s reliance on Chinese imports, which currently account for 80% of U.S. rare earth material imports. The company anticipates initiating full production at the Round Top mine as early as 2022, positioning itself as a pivotal player in the U.S. commercial and defense sectors.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.